JOHNSON & JOHNSON (JNJ)
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business